Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2022
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Prof. F. Heidel, MH Hannover | Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Fedratinib in Combination with Nivolumab
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Prof. F. Heidel, MH Hannover | Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Inrebic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2022
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Details : Undisclosed
Product Name : Inrebic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2021
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fedratinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2021
Lead Product(s) : Fedratinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fedratinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Celgene Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : Fedratinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Celgene Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : If approved, Inrebic will be the first, once-daily oral therapy to significantly reduce spleen volume and symptom burden for patients with myelofibrosis where treatment with ruxolitinib has failed or who are JAK inhibitor naïve.
Product Name : Inrebic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2020
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INREBIC® is the first new treatment for patients with myelofibrosis in nearly a decade to demonstrate a clinically meaningful reduction in spleen volume for patients in the approved population affected by this serious and rare bone marrow cancer.
Product Name : Inrebic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2020
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2020
Lead Product(s) : Fedratinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fedratinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Celgene Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : Fedratinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Celgene Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable